Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AHR | P35869 | 4/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | BLM | P54132 | 1/20 | 0.35 |
| ▸ | BACE1 | P56817 | 9/20 | 0.34 |
| ▸ | CTSD | P07339 | 1/20 | 0.32 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.32 |
| ▸ | CA12 | O43570 | 1/20 | 0.32 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
| ▸ | CA9 | Q16790 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30153529 | 0.92 | AHR (0.54) | AHRLMNAMAPTHTTBLM | |
| SCHEMBL15841475 | 0.92 | AHR (0.54) | AHRLMNAMAPTHTTBLM | |
| SCHEMBL12468801 | 0.89 | AHR (0.44) | AHRLMNAMAPTHTTBLM | |
| SCHEMBL28717064 | 0.89 | AHR (0.44) | AHRBACE1 | |
| SCHEMBL15982218 | 0.87 | AHR (0.55) | AHRLMNAMAPT | |
| SCHEMBL17703247 | 0.87 | AHR (0.55) | AHRLMNAMAPTHTTBLM | |
| SCHEMBL16426146 | 0.84 | AHR (0.45) | AHRLMNAMAPTHTTBACE1 | |
| SCHEMBL12683242 | 0.82 | AHR (0.39) | AHRCA12CA2CA9 | |
| SCHEMBL17703251 | 0.82 | AHR (0.44) | AHRBACE1AKR1B1 | |
| SCHEMBL12683146 | 0.80 | GSK3B (0.44) | AHRAKR1B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3904361-A2 | BORON CONTAINING COMPOUNDS | Merck Patent GmbH (DE) | 2021-11-03 | — | — | EP | disclosed |
| EP-3052505-B1 | BORON-CONTAINING COMPOUNDS | MERCK PATENT GMBH (DE) | 2021-06-23 | — | — | EP | disclosed |
| WO-2017023126-A1 | ORGANIC LIGHT-EMITTING COMPOUND AND ORGANIC ELECTROLUMINESCENT DEVICE USING SAME | 주식회사 두산 | 2017-02-09 | — | — | WO | disclosed |
| US-20160248015-A1 | BORON-CONTAINING COMPOUNDS | MERCK PATENT GMBH (DE) | 2016-08-25 | — | — | US | disclosed |
| US-20160248015-A1 | BORON-CONTAINING COMPOUNDS | MERCK PATENT GMBH (DE) | 2016-08-25 | — | — | US | disclosed |
| US-9150554-B2 | Fused ring inhibitors of hepatitis C | PRESIDIO PHARMACEUTICALS, INC. (US) | 2015-10-06 | — | — | US | disclosed |
| US-9150554-B2 | Fused ring inhibitors of hepatitis C | PRESIDIO PHARMACEUTICALS, INC. (US) | 2015-10-06 | — | — | US | disclosed |
| US-8999967-B2 | Tricyclic fused ring inhibitors of hepatitis C | PRESIDIO PHARMACEUTICALS, INC. (US) | 2015-04-07 | — | — | US | disclosed |
| US-8999967-B2 | Tricyclic fused ring inhibitors of hepatitis C | PRESIDIO PHARMACEUTICALS, INC. (US) | 2015-04-07 | — | — | US | disclosed |
| US-8999967-B2 | Tricyclic fused ring inhibitors of hepatitis C | PRESIDIO PHARMACEUTICALS, INC. (US) | 2015-04-07 | — | — | US | disclosed |
| US-20130296304-A1 | TRICYCLIC FUSED RING INHIBITORS OF HEPATITIS C | PRESIDIO PHARMACEUTICALS, INC. (US) | 2013-11-07 | — | — | US | disclosed |
| US-20130296304-A1 | TRICYCLIC FUSED RING INHIBITORS OF HEPATITIS C | PRESIDIO PHARMACEUTICALS, INC. (US) | 2013-11-07 | — | — | US | disclosed |
| US-20130296304-A1 | TRICYCLIC FUSED RING INHIBITORS OF HEPATITIS C | PRESIDIO PHARMACEUTICALS, INC. (US) | 2013-11-07 | — | — | US | disclosed |
| EP-2580209-A2 | INHIBITORS OF HCV NS5A PROTEIN | Presidio Pharmaceuticals, Inc. (US) | 2013-04-17 | — | — | EP | disclosed |
| WO-2012050918-A2 | TRICYCLIC FUSED RING INHIBITORS OF HEPATITIS C | PRESIDIO PHARMACEUTICAL, INC. (US) | 2012-04-19 | — | — | WO | disclosed |
| WO-2012050918-A2 | TRICYCLIC FUSED RING INHIBITORS OF HEPATITIS C | PRESIDIO PHARMACEUTICAL, INC. (US) | 2012-04-19 | — | — | WO | disclosed |
| US-20120040962-A1 | FUSED RING INHIBITORS OF HEPATITIS C | PRESIDIO PHARMACEUTICALS, INC. (US) | 2012-02-16 | — | — | US | disclosed |
| US-20120040962-A1 | FUSED RING INHIBITORS OF HEPATITIS C | PRESIDIO PHARMACEUTICALS, INC. (US) | 2012-02-16 | — | — | US | disclosed |
| WO-2011156543-A2 | INHIBITORS OF HCV NS5A PROTEIN | PRESIDIO PHARMACEUTICALS, INC. (US) | 2011-12-15 | — | — | WO | disclosed |
| WO-2011156543-A2 | INHIBITORS OF HCV NS5A PROTEIN | PRESIDIO PHARMACEUTICALS, INC. (US) | 2011-12-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160248015-A1 | BORON-CONTAINING COMPOUNDS | BIRC2, BRSK1, CTCF | AHR 1105/4885LMNA 1092/4885MAPT 1485/4885 |
| US-20130296304-A1 | TRICYCLIC FUSED RING INHIBITORS OF HEPATITIS C | HAVCR2, HCCS, LIPC | AHR 1447/4885LMNA 2669/4885MAPT 3989/4885 |
| US-20120040962-A1 | FUSED RING INHIBITORS OF HEPATITIS C | HAVCR2, HCCS, ZC3HAV1 | AHR 942/4885LMNA 2515/4885MAPT 3928/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.